自动注射器市场－全球产业规模、份额、趋势、机会及预测，依产品、适应症、最终用户、地区及竞争情况细分，2020-2030 年预测

2024 年全球自动注射器市场价值为 91.5 亿美元，预计到 2030 年将达到 204.3 亿美元，复合年增长率为 14.28%。自动注射器是一种先进的药物输送装置，旨在实现轻鬆安全的自我用药，特别适用于慢性病和紧急情况。这些装置越来越多地用于糖尿病、自体免疫疾病和过敏反应等治疗领域，无需医疗监督即可提供便利性和准确性。全球转向以患者为中心的护理以及对家庭治疗方案日益增长的偏好推动了市场的成长。自动注射器透过人体工学设计、隐藏式针头和预先测量的剂量等特性提高了治疗顺从性。随着医疗保健系统强调基于价值的护理，自动注射器在减少对医院的依赖和改善临床结果方面越来越受到关注。市场还受益于专注于将生物製剂与用户友好的输送系统相结合的药物创新，支持自我管理治疗的趋势并在全球范围内扩大自动注射器的采用。

关键市场驱动因素

慢性病和自体免疫疾病盛行率上升

主要市场挑战

製造和开发成本高

主要市场趋势

转向居家和自我管理治疗模式

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：自动注射器市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品（一次性自动注射器、可重复使用自动注射器{预填充、空}）
  • 依适应症（类风湿性关节炎、多发性硬化症、糖尿病、过敏性休克、其他）
  • 按最终使用者（家庭护理机构、医院和诊所、门诊手术中心）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美自动注射器市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲自动注射器市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太地区自动注射器市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲自动注射器市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲自动注射器市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球自动注射器市场：SWOT 分析

第 14 章：竞争格局

• Eli Lilly and Company
• SHL Medical AG
• AbbVie Inc
• Amgen Inc
• Owen Mumford Limited
• Ypsomed AG
• Teva Pharmaceutical Industries Ltd
• Biogen Inc.
• Viatris Inc
• Pfizer, Inc.
• Gerresheimer AG

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Autoinjectors Market was valued at USD 9.15 Billion in 2024 and is projected to reach USD 20.43 Billion by 2030, growing at a CAGR of 14.28%. Autoinjectors are advanced drug delivery devices designed for easy and safe self-administration of medications, particularly for chronic and emergency conditions. These devices are increasingly used across therapeutic areas such as diabetes, autoimmune diseases, and anaphylaxis, offering convenience and accuracy without the need for medical supervision. The market's growth is propelled by the global shift toward patient-centric care and the rising preference for home-based treatment options. Autoinjectors improve treatment adherence through features such as ergonomic designs, concealed needles, and pre-measured doses. As healthcare systems emphasize value-based care, autoinjectors are gaining traction for reducing hospital dependency and enhancing clinical outcomes. The market also benefits from pharmaceutical innovation focused on pairing biologics with user-friendly delivery systems, supporting the trend of self-managed therapies and broadening the adoption of autoinjectors globally.

Key Market Drivers

Rising Prevalence of Chronic and Autoimmune Diseases

The growing incidence of chronic and autoimmune diseases is a primary factor driving demand for autoinjectors. Conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis are on the rise due to aging populations, lifestyle changes, and better diagnostics. For example, global diabetes prevalence is expected to increase from 537 million adults in 2024 to 643 million by 2030. These conditions often require long-term injectable therapies, making autoinjectors an effective solution for regular, accurate self-administration. By minimizing the complexity of injections and reducing the need for clinic visits, autoinjectors help patients maintain consistent treatment schedules, thereby improving health outcomes and adherence. Their ease of use also reduces the risk of dosage errors and needle anxiety. As healthcare systems aim to reduce costs and improve quality through better disease management, autoinjectors have become integral to chronic care strategies, further strengthening their market growth.

Key Market Challenges

High Manufacturing and Development Costs

Developing and producing autoinjectors involves significant investment due to their design complexity and regulatory requirements. These devices must meet stringent safety, compatibility, and performance standards, particularly when paired with biologics. Processes such as stability testing, risk analysis, and ensuring device-drug integration contribute to high R&D expenditures. Smaller pharmaceutical and biotech firms without in-house manufacturing capabilities often face financial barriers to market entry. Customization demands for different therapeutic areas and regions, as well as integration of digital features for monitoring, further increase development costs. These challenges are especially pronounced in developing regions where pricing pressure limits widespread adoption. The capital-intensive nature of the autoinjector segment remains a major constraint on scalability and profitability for emerging market players.

Key Market Trends

Shift Toward Home-Based and Self-Administered Treatment Models

A key trend transforming the autoinjectors market is the growing emphasis on home-based healthcare. Patients managing long-term conditions are increasingly seeking alternatives to frequent clinical visits. Autoinjectors support this shift by allowing individuals to self-administer medication safely and efficiently. Their user-friendly design, automatic needle retraction, and preset dosing mechanisms reduce the risk of misuse and improve adherence. This aligns with healthcare strategies aimed at lowering costs, reducing hospital load, and empowering patients. Pharmaceutical companies are responding by developing drugs compatible with autoinjector formats, thereby extending product lifecycles and enhancing market reach. As patient education and digital health adoption grow, autoinjectors are poised to become a standard component of modern chronic disease management and at-home care models.

Key Market Players

• Eli Lilly and Company
• SHL Medical AG
• AbbVie Inc
• Amgen Inc
• Owen Mumford Limited
• Ypsomed AG
• Teva Pharmaceutical Industries Ltd
• Biogen Inc.
• Viatris Inc
• Pfizer, Inc.
• Gerresheimer AG

Report Scope:

In this report, the Global Autoinjectors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autoinjectors Market, By Product:

• Disposable Auto-injectors
• Reusable Auto-injectors

Autoinjectors Market, By Indication:

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Other

Autoinjectors Market, By End User:

• Homecare Settings
• Hospitals & Clinics
• Ambulatory Surgical Centers

Autoinjectors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autoinjectors Market.

Available Customizations:

Global Autoinjectors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Autoinjectors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Disposable auto-injectors, Reusable auto-injectors {Prefilled, Empty})
  • 5.2.2. By Indication (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Other)
  • 5.2.3. By End User (Homecare Settings, Hospitals & Clinics, Ambulatory Surgical Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Autoinjectors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Autoinjectors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Autoinjectors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Autoinjectors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Autoinjectors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Autoinjectors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Autoinjectors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Autoinjectors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. France Autoinjectors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Autoinjectors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia-Pacific Autoinjectors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Autoinjectors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Autoinjectors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Autoinjectors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Autoinjectors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Autoinjectors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. South America Autoinjectors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Autoinjectors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Autoinjectors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Autoinjectors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. Middle East and Africa Autoinjectors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Autoinjectors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Autoinjectors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Autoinjectors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Autoinjectors Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. SHL Medical AG
• 14.3. AbbVie Inc
• 14.4. Amgen Inc
• 14.5. Owen Mumford Limited
• 14.6. Ypsomed AG
• 14.7. Teva Pharmaceutical Industries Ltd
• 14.8. Biogen Inc.
• 14.9. Viatris Inc
• 14.10.Pfizer, Inc.
• 14.11.Gerresheimer AG

15. Strategic Recommendations

16. About Us & Disclaimer